Payment overview · 2025
General Payments
$364.48
19 reported records · 13 companies
Healthcare provider profile · identity verified
Steven Marc Liebowitz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RALEIGH, NC · NPI 1386646453
Verified facts
What the public records show
CMS Open Payments records show Steven Marc Liebowitz, M.D. received $364.48 in general payments during 2025 across 19 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 522 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 522 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.00 | 14.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.86 | 14.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.38 | 14.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.22 | 9.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.61 | 8.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.41 | 6.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.67 | 5.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.49 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.61 | 4.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.37 | 4.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.43 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.50 | 4.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.93 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $364.48 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.00 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.81 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.61 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 522 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
522 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
226 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
522 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 870 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 774 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 756 | 151 |
| Gabapentin | Gabapentin | 637 | 90 |
| Eliquis | Apixaban | 522 | 58 |
| Sertraline Hcl | Sertraline Hcl | 514 | 46 |
| Furosemide | Furosemide | 420 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 415 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 381 | 94 |
| Losartan Potassium | Losartan Potassium | 324 | 66 |
| Valsartan | Valsartan | 323 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 291 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 280 | 35 |
| Potassium Chloride | Potassium Chloride | 266 | 29 |
| Donepezil Hcl | Donepezil Hcl | 247 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 52 |
| Trazodone Hcl | Trazodone Hcl | 243 | 47 |
| Carvedilol | Carvedilol | 234 | 29 |
| Omeprazole | Omeprazole | 234 | 49 |
| Metformin Hcl | Metformin Hcl | 229 | 38 |
| Jardiance | Empagliflozin | 226 | 34 |
| Mirtazapine | Mirtazapine | 221 | 37 |
| Lisinopril | Lisinopril | 181 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 46 |
| Buspirone Hcl | Buspirone Hcl | 173 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 25 |
| Alprazolam | Alprazolam | 159 | 42 |
| Memantine Hcl | Memantine Hcl | 159 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 25 |
| Glimepiride | Glimepiride | 155 | 23 |
| Montelukast Sodium | Montelukast Sodium | 154 | 38 |
| Simvastatin | Simvastatin | 148 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 33 |
| Spironolactone | Spironolactone | 144 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 35 |
| Xarelto | Rivaroxaban | 128 | 16 |
| Famotidine | Famotidine | 124 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 16 |
| Allopurinol | Allopurinol | 116 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 17 |
| Tradjenta | Linagliptin | 110 | suppressed |
| Ezetimibe | Ezetimibe | 109 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 108 | 17 |
| Trulicity | Dulaglutide | 107 | 14 |
| Prednisone | Prednisone | 105 | 31 |
| Irbesartan | Irbesartan | 98 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 97 | 17 |
| Lorazepam | Lorazepam | 96 | 25 |
| Metformin Hcl Er | Metformin Hcl | 93 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 27 |
| Olanzapine | Olanzapine | 90 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | suppressed |
| Atenolol | Atenolol | 83 | 22 |
| Tramadol Hcl | Tramadol Hcl | 81 | 34 |
| Divalproex Sodium | Divalproex Sodium | 79 | suppressed |
| Synthroid | Levothyroxine Sodium | 79 | 15 |
| Celecoxib | Celecoxib | 78 | 20 |
| Baclofen | Baclofen | 74 | 15 |
| Clonidine Hcl | Clonidine Hcl | 71 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 13 |
| Azithromycin | Azithromycin | 66 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 23 |
| Divalproex Sodium Er | Divalproex Sodium | 66 | suppressed |
| Brilinta | Ticagrelor | 64 | suppressed |
| Meloxicam | Meloxicam | 62 | 15 |
| Gemtesa | Vibegron | 61 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 61 | suppressed |
| Repatha Sureclick | Evolocumab | 61 | suppressed |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 59 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 12 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 55 | 11 |
| Latanoprost | Latanoprost | 55 | 17 |
| Entecavir | Entecavir | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 35 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Bumetanide | Bumetanide | 48 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 41 |
| Novolog Flexpen | Insulin Aspart | 48 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 11 |
| Clonazepam | Clonazepam | 44 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Cyclosporine | Cyclosporine | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 40 | suppressed |
| Cefdinir | Cefdinir | 39 | 29 |
| Finasteride | Finasteride | 38 | 11 |
| Paxil Cr | Paroxetine Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 20 |
| Ondansetron Odt | Ondansetron | 36 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 25 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 15 |
| Glipizide | Glipizide | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 24 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 14 |
| Lagevrio (Eua) | Molnupiravir | 27 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 21 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Trimethoprim | Trimethoprim | 21 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Zaleplon | Zaleplon | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $364.48 · 19 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, CAPVAXIVE, ELIQUIS, GEMTESA, INCEPTIV, KISUNLA, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, REPATHA, REXULTI, Rybelsus, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error